Results 341 to 347 of about 9,352,293 (347)

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Lancet, The, 2002
Stephen B Hanauer
exaly  

Crohn's disease.

Hepato-gastroenterology, 1990
Tytgat, K. M., Lygidakis, N. J.
openaire   +2 more sources

Genetics of Crohn disease, an archetypal inflammatory barrier disease

Nature Reviews Genetics, 2005
Stefan Schreiber, Philip Rosenstiel, Mario Albrecht   +2 more
exaly  

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Gastroenterology, 2007
J. Colombel, W. Sandborn, P. Rutgeerts, R. Enns, S. Hanauer, R. Panaccione, S. Schreiber, Daniel Byczkowski, Ju Li, J. Kent, P. Pollack   +10 more
semanticscholar   +1 more source

Knot Crohn's disease

The Lancet, 1996
S, Roy, O, Hughes, K, Mukherjee, B M, Stephenson   +3 more
openaire   +2 more sources

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Gut, 2012
Bruce E Sands, Marc Vandemeulebroecke, Peter D R Higgins   +2 more
exaly  

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

Lancet, The, 2016
Damián García-Olmo, Gert Van Assche, Walter Reinisch   +2 more
exaly